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Abstract
Background: Although sudden cardiac death (SCD) is recognized as a distinct cause of death in patients with end
stage renal disease (ESRD), its incidence has not been well summarized.
Methods: We performed a systematic review and meta-analysis of the literature based on a protocol developed a
priori. We searched MEDLINE and EMBASE (inception to March 2015) for randomized controlled trials and cohort
studies reporting the incidence of SCD in adult patients with ESRD on hemodialysis or peritoneal dialysis. We
collected data on number of SCD as well as the definition of SCD for each individual study. A random-effects
model was used to summarize the incidence of SCD. We conducted subgroup analyses to explore sources of
heterogeneity.
Results: Forty two studies (n = 80,382 patients) were included in the meta-analysis. The incidence of SCD among
adults with ESRD ranged from 0.4 to 10.04 deaths per 100 person-years. The definitions and assessment of SCD
varied across the included studies. There was evidence of significant heterogeneity (I2 = 98; p < 0.001), which was
not explained by subgroup analyses stratified by mean age, proportion of hypertensive or diabetic patients,
follow-up time, study size, or type of cohort studied.
Conclusion: Current estimates of the incidence of SCD among adults with ESRD vary widely. There is a need for
further studies to more accurately estimate the incidence of SCD in patients with ESRD.
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Background
The rising prevalence of end stage renal disease (ESRD)
is a global public health concern [1–3]. Adults with
ESRD have mortality rates up to 30-fold higher than the
general population, with cardiovascular disease the
major cause of death, accounting for approximately 38 %
of all deaths among patients receiving chronic dialysis
[4]. Sudden cardiac death (SCD), typically defined as
death due to cardiac arrest occurring suddenly and
within 1 h of witnessed symptom onset (or occurring
within 24 h since last the patient had been known to be
well), is responsible for the majority of cardiovascular-
related deaths in patients with ESRD with studies reporting
that up to 25 % of all deaths in this high-risk population is
attributable to SCD [5]. However, there is substantial
inconsistency in the definition of SCD, leading to wide
variations in the reported SCD rates among individuals
with ESRD [6]. Narrative reviews have attempted to
summarize SCD rates in patients with ESRD [5, 7, 8], how-
ever, these reviews have not been systematically conducted,
and their primary purpose was to summarize possible
causes and mechanisms of SCD. We therefore sought to
conduct a systematic review and meta-analysis of random-
ized trials and cohort studies to determine the incidence of
SCD in adults with ESRD.
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Methods
Data sources and searches
We performed a systematic review of the literature based
on a protocol developed a priori in accordance with rec-
ommendations from the Meta-analysis of Observational
Studies in Epidemiology and Preferred Reporting Items
for Systematic Reviews and Meta-analyses statements [9].
We identified relevant studies by searching Ovid
MEDLINE (from 1950 to March 2015) and EMBASE
(from 1980 to March 2015) without language restric-
tions. All relevant text words and Medical Subject
Heading (MeSH)/Emtree terms for chronic kidney
disease (“Renal Insufficiency Chronic”, “Kidney Failure”,
“Kidney Diseases”, “Renal Replacement Therapy”, “Uremia”,
“Dialysis”, “Hemodialysis”, “Hemofiltration”, “Peritoneal
Dialysis” or “Predialysis”) and SCD (“Heart Arrest” or
“Sudden Cardiac Death” or “Sudden Arrhythmic Death”)
were combined separately using the “OR” Boolean oper-
ator. These two search themes were then combined using
the Boolean “AND” operator (Additional file 1). To
identify additional relevant studies, we manually screened
reference lists from identified studies and contacted
field experts.
Study selection
Two independent reviewers (SR and AZ) screened all
abstracts identified by the search using a standardized
approach to determine relevant articles for full-text re-
view. All cohort studies and randomized controlled trials
conducted in adults (age ≥18 years) with ESRD receiving
dialysis (hemodialysis or peritoneal dialysis) and report-
ing on ≥5 events of SCD were eligible for inclusion in
the systematic review. Studies examining the incidence
of SCD in transplant recipients were excluded. Any dis-
agreement in study inclusion was resolved by a third re-
viewer (MJ).
Data extraction
A standardized data extraction spreadsheet was devel-
oped and used to abstract data on baseline participant
characteristics including age, sex, body mass index, sys-
tolic and diastolic blood pressure, proportion of patients
with diabetes, hypertension, myocardial infarction, cor-
onary artery disease, current smokers, alcohol intake,
and ethnicity, as well as follow-up duration, and SCD (as
defined by authors).
Study quality assessment
Study quality was judged based on standard criteria rele-
vant to systematic reviews of cohort studies [10] and the
Cochrane Risk of Bias for randomized controlled trials.
For observational studies, the criteria assessed were pa-
tient attrition, acknowledgement of sources of funding,
clear description of SCD, clear description of study
participant characteristics, number of participants at
each stage of study and reasons for ineligibility, propor-
tion of eligible participants described, evidence of con-
secutive or random sampling, clear descriptions of
inclusion criteria and sources and methods of participant
selection and study setting, and locations and dates for
recruitment. For randomized trials, study quality was
judged by proper conduct of randomization, treatment
allocation concealment, use of intention-to-treat, blind-
ing of participants and outcome assessment, and evi-
dence for incomplete or selective reporting of outcome.
For each criterion, a study was considered to be at low
risk if the information for the assessment was provided
and there was sufficient evidence to fulfill criteria re-
quirement. A study was considered at medium risk if
there was evidence to suggest that part of the criteria re-
quirement was completed, however, not sufficiently to
reduce bias. A study was considered to be high risk if no
information was provided or if no information regarding
a failure to meet criteria requirements was provided.
Outcome
We collected data on the number of SCD events as well
as the definition of SCD for each individual study.
Data synthesis and analysis
The incidence of SCD in each of the individual studies
and the corresponding Wilson score 95 % confidence in-
tervals (CIs) for binomial data were calculated [11]. In
calculating the incidence, the total number of patients at
risk was multiplied by the mean or median follow up in
each study to obtain the denominator (person-years of
follow-up) and the number of SCD events contributed
to the numerator. Incidence rates were expressed as per
100 person-years.
Summary estimates of incidence and incidence rates of
SCD were obtained using a DerSimonian and Laird ran-
dom effects model [12]. The percentage of variability
across studies due to heterogeneity beyond chance was
estimated using I2 statistics [13] and Cochran’s Q tests
of homogeneity. We explored sources of heterogeneity
across the estimates of SCD cumulative incidence using
univariate meta-regression [13] and subgroup analysis by
comparing summary results obtained from subsets of
studies dichotomized based on study mean age, propor-
tion of hypertensive patients, proportion of diabetic pa-
tients, follow-up duration, study mean BMI, study mean
systolic blood pressure, study mean diastolic blood pres-
sure, method of SCD ascertainment (chart review vs.
rigorous assessment), and type of cohort (general popu-
lation vs. selective). We classified studies as a general
population cohort if the study encompassed a wide
spectrum of patients on dialysis with a broad eligibility
criterion and as a selective cohort if the study aimed to
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capture a subset of patients on dialysis. A two-sided
p-value <0.05 was considered statistically significant for
all analyses. All statistical analyses were performed with
Stata/IC version 12.0 (Stata Corp., College Station, TX,
USA).
Results
Study and included patient characteristics
The literature search yielded a total of 3,854 citations, of
which 488 qualified for full text review (Fig. 1). The final
analysis included 42 studies with 80,382 patients with
ESRD reporting on 8,574 SCD events. The characteris-
tics of the studies included in the systematic review are
shown in Additional file 2. Of the 42 studies, 40 were co-
hort studies, 1 was a randomized controlled trial, and 2
were observational analyses of randomized controlled tri-
als. 14 were from Asia [14–27], 17 from Europe [28–44],
7 from North America [30, 45–52], 1 from Oceania [53], 2
from South America [54, 55], and 1 international study
conducted across centers in Europe, North America and
Oceania [56]. The studies were published between 1985
and 2014 and the number of patients enrolled ranged
from 22 to 37,765. Most studies were conducted in
hemodialysis patients (71 %) with only two enrolling spe-
cifically peritoneal dialysis patients [27, 38]. The mean age
of patients ranged from 44 to 71 years and the proportion
of males ranged from 48 to 83 %. Data on comorbidities
were generally limited. The proportion of patients with
hypertension across the included studies ranged between
5 and 91 % while those with diabetes ranged between 6
and 100 %.
Study quality
The assessment of the risk of bias in the included studies
is summarized in Fig. 2. Thirty-eight studies provided in-
formation regarding the setting, locations and dates of
studies [14–19, 21–37, 40–43, 45–48, 51–57]. Further-
more, 34 of 42 studies (81 %) had clearly defined eligibility
criteria [14, 15, 17–19, 21, 24–31, 33–38, 40–44, 46–48,
51–57]. Twenty one (50 %) studies had a low risk of selec-
tion bias based on their random or consecutive sampling
method [15, 21, 24, 26, 29–31, 34–36, 41–43, 46, 48, 51,
52, 54, 55, 57]. The eligibility criteria and participant rate
were described adequately in 29 studies (69 %) [14, 15, 19,
21, 24–31, 33–35, 37, 41–44, 46–48, 51–55, 57], and 15
studies (36 %) [19, 21, 24, 28–31, 35, 37, 42, 44, 47,
Fig. 1 PRISMA flow diagram showing the identification process for eligible studies
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48, 54, 55] described the flow of participants and rea-
sons of ineligibility. Thirty one studies (74 %) pro-
vided a clear description of the characteristics of the
included participants [14, 15, 17–19, 21, 24, 26–35,
37, 41–46, 48, 51–56] and 24 studies (57 %) appropri-
ately defined sudden cardiac death [15, 17, 19–21, 23,
27, 29, 31, 33–37, 41, 42, 46, 51–57]. Additionally, 26
and 13 studies acknowledged the sources of funding
[14, 16, 18, 21, 23, 24, 26–29, 31–34, 36, 38, 41–43,
45, 47, 51–54, 56] and attrition [17–19, 21, 24, 27,
29, 31, 35, 37, 48, 51, 53, 55], respectively.
Of the three studies with data from clinical trials, the
overall risk of bias was low. Although only one study
provided details about allocation bias [32], the risk of
bias associated with blinding, randomization and select-
ive outcome reporting was low.
Definition of SCD and SCD assessment
The definition of SCD varied among the included
studies. Twenty-six (of which 3 were from trials) of the
43 studies provided a definition for SCD [15, 17–21, 23,
27, 29, 31, 32, 34–37, 41, 42, 46, 48, 51–54, 56, 57].
Seventeen studies included time in their definition of
SCD [15, 17, 19–21, 23, 27, 29, 31, 34–36, 41, 42, 46, 52,
54]. Eight studies included hyperkalemia, cardiac
arrhythmia and cardiac arrest in their definitions of SCD
[21, 32, 44, 48, 51–53, 56] and one study broadened their
definition to include any unwitnessed and unexpected car-
diac death [52]. The most common definitions of SCD
were “death occurring within an hour of symptom onset
with no clinical support for another cause” (n = 12; 28 %)
where SCD incidence ranged from 0.76 to 7.09 SCD
events per 100 person years and “death occurring within
24 h of symptom onset with no clinical support for an-
other cause” (n = 5; 12 %) where SCD incidence ranged
from 2.09 to 3.38 SCD events per 100 person-years.
Similar to the variability in the definition of cardiac
death, the rigor of assessment of SCD varied among the
included studies. Seven studies did not provide any in-
formation about the assessment of SCD [14, 23, 33, 38,
43, 47, 49]. Nineteen studies assessed SCD using death
certificates and chart reviews [15, 16, 18, 20, 24, 25,
28–32, 34–36, 41, 44, 48, 52, 57] and 16 studies
assessed SCD using a more rigorous method, i.e., using
blinded assessment, physician interviews, coroner’s report
and/or witness interviews [17, 19, 21, 22, 24, 26, 27, 35,
37, 40, 42, 45, 46, 50, 51, 53–56].
Estimated incidence rates of sudden cardiac death
A total of 8,574 SCD events occurred in 80,382 partici-
pants over a follow-up that ranged between 1.5 and
10 years. The estimated incidence rate of SCD among
adults with ESRD ranged from 0.4 to 10.04 deaths per
100 person-years (Fig. 3). We observed evidence of
significant heterogeneity across the included studies
(I2 = 98 %, p < 0.001) and therefore did not calculate a
summative estimate of the incidence rates. Additionally,
the incidence rates were not significantly different be-
tween the two most common definitions of SCD (p = 0.1).
The incidence rate in studies that included time in their
Fig. 2 Risk of Bias Assessment
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definition was 2.98 SCD per 100 person-years (95 % CI:
2.87–3.11) and was 2.66 SCD per 100 person-years 95 %
CI: 2.57–2.76) for studies that included hyperkalemia in
their definition.
Subgroup analysis
Studies with greater than or equal to 32 % of subjects
with diabetes had a greater incidence of SCD compared
to studies with less than 32 % of subjects with diabetes
(p = 0.05; Fig. 4). Studies that had greater than or equal
to 3.4 years of follow up had a lower estimated incidence
rate of SCD compared to studies with less than 3.4 years
of follow up (p = 0.04; Fig. 4).
Discussion
Our quantitative review of randomized controlled trials
and cohort studies including over 81,000 patients with
ESRD on dialysis shows that the reported incidence of
SCD in ESRD varies widely, ranging from 0.4 to 10.04
deaths per 100 person-years. In addition, there is a lack
of standardization in the definitions of SCD in ESRD as
well as the methods of its assessment.
The lack of standardization and variability in SCD def-
inition has previously been identified in the general
population [58]. We have identified similar heterogeneity
in SCD definition among dialysis patients as well as in-
consistencies in adjudication methods.
The current lack of a standardized definition of SCD
in ESRD, in addition to the varied methods of its assess-
ment, are likely to be major contributors to the wide
range of estimates reported. As was the case with the
systematic review conducted in the general population
[58], studies with the primary aim of determining the in-
cidence of SCD was lacking as we observed only 1 study
specifically focused on the assessment of the incidence
of SCD.
Fig. 3 Estimated incidence rate
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Large, population-based renal registries such as the
United States Renal Data System (USRDS) and the
Australia and New Zealand Dialysis and Transplant
(ANZDATA) Registry have reported causes of death,
including SCD (cardiac arrest), among dialysis patients.
While large-scale multicenter studies are currently needed
to further validate results derived from these registries, it
is reassuring that our results are largely consistent with
registry-based SCD the incidence rate reported by the
United States Renal Data System (USRDS) (4.3 events per
100 person-years) [59] and the proportion of cardiac death
as reported by The Australia and New Zealand Dialysis
and Transplant Registry (ANZDATA) (2.3 %) [60].
Our subgroup analysis found that studies with higher
proportion of patients with diabetes reported a higher
incidence of SCD. Diabetes has been found to increase
SCD risk in both healthy subjects and subjects with
CKD. Indeed, the ‘Paris Prospective Study I’, a 23-year
long prospective study of 7,000 males suggested that dia-
betes was associated with a SCD risk ratio of 2.2, higher
than any other factor evaluated in the study [61]. More-
over, an analysis of 400 SCD cases by Karnik et al. in a
cohort of hemodialysis patients found that patients who
died of SCD were more likely to have diabetes compared
to patients who died of other causes (61.8 vs. 46.8 %)
[62]. Finally, we found that studies with a longer follow-
up time had a higher estimated incidence of SCD com-
pared to those with a shorter follow-up time. While
there were no apparent differences in comorbidities or
SCD assessment between these studies, one possible ex-
planation could be a higher chance of loss to follow-up
in longer studies compared to shorter studies. This,
however, cannot be confirmed as many studies did not
report on attrition.
Our systematic review has limitations. Our analysis
was restricted by the overall paucity of studies reporting
Fig. 4 Subgroup analysis
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on SCD incidence and was based on published study-
level data. With only two studies reporting incidence
rates, we were limited in our ability to assess the inci-
dence of SCD in patients on dialysis. We were limited in
our ability to explore the effects of race on SCD inci-
dence rate through subgroup analyses as only 6 of the
43 included studies reported on race of the subjects.
Another limitation of this study is the lack of inclusion of
all large registry data. While the primary purpose of this
study was to summarize data from published studies, large
national registry databases provide important information
with regards to SCD in the dialysis population and future
studies should focus on verifying and improving the
accuracy of these databases with large validations studies
designed to assess the incidence of SCD in patients with
ESRD. This study highlights the need for the standard-
ization of SCD definition and ascertainment, and for
larger multicenter studies that aim to determine the inci-
dence of SCD in this high risk population.
Conclusion
The reported incidence of SCD in patients with ESRD var-
ies widely and studies specifically designed to determine
the incidence of SCD in adults with ESRD are limited. As
SCD remains a major concern in the patients with ESRD
our findings emphasize that further investigation to deter-
mine the incidence of SCD within this patient population
is needed.
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